Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
TransCode Therapeutics Inc. (RNAZ) had Return on Tangible Equity of 26.72% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-36.27M |
|
-- |
|
-- |
|
$27.98M |
|
$-27.98M |
|
$-6.45M |
|
$-34.44M |
|
$-34.44M |
|
$-34.66M |
|
$-34.66M |
|
$-34.66M |
|
$-34.66M |
|
$-27.98M |
|
$-27.87M |
|
0.69M |
|
0.69M |
|
$-52.59 |
|
$-52.59 |
|
| Balance Sheet Financials | |
$21.98M |
|
$0.37M |
|
$140.41M |
|
$162.40M |
|
$3.49M |
|
-- |
|
$148.57M |
|
$152.06M |
|
$10.34M |
|
$-129.71M |
|
$10.34M |
|
0.92M |
|
| Cash Flow Statement Financials | |
$-19.52M |
|
$-0.00M |
|
$31.52M |
|
$5.81M |
|
$17.81M |
|
$12.00M |
|
$0.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.52M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-335.36% |
|
|
Return on Tangible Equity |
26.72% |
-21.34% |
|
-335.36% |
|
$11.27 |
|
$-28.31 |
|
$-28.30 |
|